期刊
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
卷 24, 期 9, 页码 S20-S25出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/IGC.0000000000000289
关键词
Clear cell carcinoma of the ovary (CCC); Deep venous thrombosis; Glycogen; Hepatocyte nuclear factor-1 beta; WT1; Pulmonary embolism; Ethnics; ARID1A; PIK3CA; PPM1D; PPP2R1A; KRAS; Cytoreductive surgery; Paclitaxel; Platinum; Irinotecan hydrochloride; Cisplatin; PI3K/AKT/mTOR
资金
- Cancer Research UK [15600] Funding Source: researchfish
Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than high-grade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据